Elicio Therapeutics, Inc. Income Statement
ELTX|2 years of annual SEC 10-K data (FY2021-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Elicio Therapeutics, Inc. reported $28M in revenue and $55M in net loss for FY2022. Revenue increased 883.1% from FY2021 to FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.36 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 |
|---|---|---|
| Revenue | $28.3M | $2.9M |
| Cost of Revenue | $433.0K | $1.2M |
| SG&A Expense | $18.5M | $18.0M |
| R&D Expense | $48.7M | $39.0M |
| Operating Income | -$39.3M | -$55.3M |
| Interest Expense | -$1.8M | -$8.8M |
| Income Tax | $0 | $0 |
| Net Income | -$54.6M | -$80.1M |
| EPS (Basic) | -$1.93 | -$5.43 |
| EPS (Diluted) | -$1.93 | -$5.43 |
| Shares Outstanding | 30.0M | 15.3M |
| Operating Margin | -138.8% | -1919.2% |
| Profit Margin | -192.8% | -2781.5% |